We are thrilled to congratulate the WAINUA team from AstraZeneca on being selected as an ELITE100 Marketing Team! Don’t miss a chance to meet them and all of our other incredible ELITE winners tomorrow on June 18th at 230 FIFTH Rooftop in NYC for our celebration of the pharma industry’s best and brightest: https://lnkd.in/g4nE39eW
PM360 Magazine’s Post
More Relevant Posts
-
Future Pharma 2024 is around the corner! Adam Alfi and Mai Shafei are attending the World’s Leading Pharma Commercialization Event. Stay tuned for more insights from the event! #futurepharma2024
To view or add a comment, sign in
-
-
Listen to Mohammed Ali of Astellas Pharma on why he is coming back to #DPHARM for the 9th year in a row! "It is a great opportunity to understand what is happening across each other's organizations, where the opportunities and challenges are, and potentially to find solutions together." Learn more about DPHARM: DPHARMconference.com #DPHARM2024 #clinicalinnovation #clinicalresearch #clinicaltrials
To view or add a comment, sign in
-
On both sides of the Atlantic pharma companies are presenting cases to the courts and to national regulators that the innovation cash pipelines will be disrupted, forcing them to either cut back and delay launches or move operations to Asia Pacific or Latin America. Find out more in our newly published whitepaper featuring industry experts: · Christoph Glaetzer, Dipl.Kfm., Chief Global Value and Access at Johnson & Johnson Innovative Medicine · Ricardo Werner Marek, President Europe & Canada at Takeda · Andy Powrie-Smith, Executive Director, Communications & Partnerships at EFPIA - European Federation of Pharmaceutical Industries and Associations Access the full whitepaper here: https://bit.ly/3Vh46Y2
To view or add a comment, sign in
-
-
Following the launch of the Harnessing the Full Potential of Real-World Data Enhance Clinical Trials Roundtable Discussion (12 June 2024, 11am-12pm EST/4pm-5pm BST, 60 minutes), we had the opportunity to sit down with the content director Prishu Kagra to discuss the key themes of the session. Specialists from leading #Pharma organizations Sanofi, Novartis, GSK, AstraZeneca and Parexel will be sharing their best practice use cases for implementing real-world data and evidence to drive innovation, improve patient outcomes, and advance healthcare delivery in clinical trials. Swipe below to see the key themes of the upcoming virtual roundtable >>> Register FREE: https://lnkd.in/eSPseiVg #AMGWorld #Technology #ClinicalOperations #ClinicalInnovation #Digitalization #RealWorldData
To view or add a comment, sign in
-
Two weeks ago, over 60 of us came together in NYC for a fantastic day of discussion at the Bioethics International Roundtable as leaders from across the biopharmaceutical industry. As always, the event was inspiring as we explored key topics such as clinical trial diversity, patient centricity, access to medicines globally, and the rapidly evolving focus on ESG in our industry. I was particularly inspired by the discussion focused on sharing individual results to clinical trial participants, a topic that has been a passion for me since my GSK days where I was deeply involved in the development of plain language summaries, internally and externally, as it was a new component of clinical trial transparency spurred on by the EU Clinical Trial Regulation requirement. From that point, it simply made sense to move from sharing aggregate results to sharing individual results. So proud to represent Legacy Health Strategies in this forum and to have developed the capability to operationalize sharing of individual and aggregate results via a digital communication platform connecting sponsors and participants, before, during and after clinical trials. Looking forward to collaborating further to ensure the industry lives up to its full potential for good! - CEO Jessica Scott, MD, JD #BioethicsInternational #BEI #HealthEquity #ClinicalTrials #PatientEngagement #ESG #Transparency #LegacyHealthStrategies #DrugDevelopment #RoundTable #Pharma #NYC
To view or add a comment, sign in
-
-
Serial entrepreneur, CEO PharmaTrace and Kuiperpartners- Pharma Management Consultant- Blockchain NFT and Web3 Expert- Angel Investor
Thanks Sanofi for putting your trust on us PharmaTrace . Now after NVIDIA elite startup program, now another big milestone which shows our dedication and perseverance to put our marks within healthcare and Pharma ecosystems. We don’t talk we do! Danke merci chokran Dm me or contact us for our various portfolio in #competitiveintelligene #trackandtrace #serialization #blockchain #AI #management
🎉We are thrilled to announce that PharmaTrace is now a proud member of the Sanofi Innovation Ecosystem Platform! 🎉 Joining this prestigious program marks yet another significant milestone in our journey as a reputable service provider in the pharmaceutical industry. We are immensely grateful for the trust and confidence shown in us by Sanofi, a leading innovator in healthcare. Joining the Sanofi Innovation Ecosystem Platform means big things for us. We're getting seen by Sanofi's teams worldwide – that's over 100 countries and about 100,000 employees! It's our chance to show off what we do best and prove our value. Being part of this platform isn't just about visibility; it's about making meaningful connections that make a real difference. We are eager to leverage this partnership to its fullest potential, collaborating with Sanofi to shape the future of healthcare and deliver solutions that benefit patients worldwide. Thank you to Sanofi and Sasalet. Kalulu for this incredible opportunity, and here's to an exciting journey ahead! 🌟 #PharmaTrace #SanofiInnovationEcosystem #HealthcareInnovation #PartnershipGoals #Sanofi #HrealthTech #Innovation #Pharma #Pharmaceuticals
To view or add a comment, sign in
-
-
L.E.K.'s latest Executive Insight with Pierre Jacquet, M.D., Ph.D. Ricardo Brau Anne Dhulesia details a comprehensive analysis of Biopharma M&A trends and implications for Pharma executives and Boards. With over a decade of experience advising clients on Biopharma M&A, our analyses uncovered key trends in the market that may continue to influence deal-making in 2024 and beyond. Importantly, our work closely examined clinical outcomes and commercial performance of historical M&A deals, highlighting key insights for industry decision-makers to consider for transacting deals in today's environment. Given these learnings, we highlight 5 key strategic priorities to successfully navigate the current M&A environment. Link:
To view or add a comment, sign in
-
On the cross-country flight home from a wonderful and busy BIO International Convention, I spent some time reflecting on three years here at the National Pharmaceutical Council. I still remember flying to DC as the brand-new President and CEO of the organization in June 2021 – a trip that simultaneously feels like yesterday and a lifetime ago, given the changes in the industry, health policy, and research environment. The work of NPC has never been more relevant — or more important. We have a great team, and this team appreciates the challenges we face. Here are three reflections I’d offer for anyone interested in the future of innovation. • To meet the challenges of today and tomorrow, NPC has built new capabilities that allow us to build on our 70-year legacy as we conduct rigorous, policy-relevant research and communicate it with impact. I invite you to learn more about the value we provide to NPC members and the benefits member companies experience. https://lnkd.in/etCWVqTE • NPC’s research informs many of the important policy conversations going on right now. To stay up to date on our latest, I hope you subscribe to the NPC This Week Newsletter to get a weekly look-ahead at the policy, research, and industry conversations that matter to the future of biopharmaceutical innovation. https://lnkd.in/eBAj7B_B • I’m proud of the team at NPC and what we’ve accomplished — while recognizing the challenges in front of us. If you’d like to see more of our recent research, analysis, and work, check out our 2023 Annual Report. https://lnkd.in/eB6u2nWd I’ve loved every minute of the past three years and look forward to many more. These aren’t challenges we can solve alone, and it has never been more important for drugmakers, payers, and policymakers to understand the ecosystem and work together for the benefit of patients. If we haven’t spoken in a while, I’d love to hear from you, whether in the DMs, email, or phone. #pharma #innovation #healthpolicy
To view or add a comment, sign in